多药耐药相关蛋白质在鼻咽癌中的表达及其临床意义

The expression and clinical significance of multidrug resistance-associated proteins in patients with nasopharyngeal carcinoma

目的探讨多药耐药基因1（MDR1）、谷胱甘肽S转移酶（GST-）、拓扑异构酶Ⅱ（TOPⅡ）和多药耐药相关蛋白（MRP）在鼻咽癌组织中的表达及其临床意义。方法采用免疫组化法检测45例鼻咽癌患者化放疗前鼻咽癌组织MDR1、GST-、TOPⅡ和MRP蛋白表达。T3-4 N2-3期和T2N1期患者鼻咽癌患者采用同期化疗,其中T3-4 N2-3期鼻咽癌患者采用新辅助化疗,化疗结束后7-14 d放疗。化放疗结束后6个月进行评价。结果 GST-、TOPⅡ和MRP蛋白表达与鼻咽癌病理类型无关（P=0.933,0.360,0.944）,而MDR1表达与病理类型有关（P=0.037）;MDR1、GST-、TOPⅡ和MRP蛋白表达与临床分期和近期疗效均不相关（均P〉0.05）。结论 MDR1、GST-、TOPⅡ和MRP表达对鼻咽癌临床分期和近期疗效无意义。

Objective To explore the clinic significance of Multi-drug resistant protein expression（ MDR1、GST-、TOPⅡ、MRP） in patients with nasopharyngeal carcinoma. Methods MDR1,GST-,TOPⅡ,MRP protein expression were determined by immunohistochemistry in 45 patients with nasopharyngeal carcinoma before radiotherapy and chemotherapy. Those patients,with T3 - 4,N2 - 3 and T2N1 stages were treated with neoadjuvant chemotherapy,and 7 - 14 day after followed by radiotherapyr. The response of chemotherapy and radiotherapy in NPC patients was evaluated at six months. Results The expression rate of MDR1 was correlated with pathology types,but the expression of GST-,TOPⅡ and MRP were not associated with pathology types. The expression of MDR1,GST-,TOPⅡ and MRP were not associated with clinical stage and short-term effects. Conclusions It was not significance to evaluate the relation of the expressions of MDR1,GST-,TOPⅡ,MRP protein and clinical stage and short-term therapeutic effect.